Drug General Information |
Drug ID |
D07GXY
|
Former ID |
DIB020732
|
Drug Name |
piribedil
|
Drug Type |
Small molecular drug
|
Indication |
Discovery agent
|
Investigative |
[1]
|
Structure |
|
Download
2D MOL
|
Formula |
C16H18N4O2
|
InChI |
InChI=1S/C16H18N4O2/c1-4-17-16(18-5-1)20-8-6-19(7-9-20)11-13-2-3-14-15(10-13)22-12-21-14/h1-5,10H,6-9,11-12H2
|
InChIKey |
OQDPVLVUJFGPGQ-UHFFFAOYSA-N
|
PubChem Compound ID |
|
PubChem Substance ID |
3318349, 5518527, 8152983, 10589522, 11111687, 11111688, 11113867, 11467008, 11468128, 11486666, 14776022, 26752039, 29223931, 47291247, 47365330, 47515441, 47662430, 47736619, 47885534, 47885535, 48110578, 48334631, 48853191, 49699322, 50036468, 50104696, 50647529, 51091642, 57309591, 57322489, 61104879, 85209232, 85788361, 85788799, 88943151, 90341513, 92308933, 92719149, 93616730, 103113732, 104171222, 104307610, 105856731, 117603465, 124365751, 124750130, 124881234, 124881235, 124881236, 125433414
|
Target and Pathway |
Target(s) |
D(3) dopamine receptor |
Target Info |
Agonist |
[2]
|
5-hydroxytryptamine 2B receptor |
Target Info |
Antagonist |
[2]
|
5-hydroxytryptamine 1A receptor |
Target Info |
Agonist |
[2]
|
D(4) dopamine receptor |
Target Info |
Antagonist |
[2]
|
D(2) dopamine receptor |
Target Info |
Agonist |
[2]
|
Alpha-2C adrenergic receptor |
Target Info |
Antagonist |
[2]
|
KEGG Pathway
|
Neuroactive ligand-receptor interaction
|
Dopaminergic synapsehsa04020:Calcium signaling pathway
|
Gap junction
|
Serotonergic synapse
|
Inflammatory mediator regulation of TRP channelshsa04024:cAMP signaling pathway
|
Serotonergic synapsehsa04080:Neuroactive ligand-receptor interaction
|
Dopaminergic synapsehsa04015:Rap1 signaling pathway
|
cAMP signaling pathway
|
Dopaminergic synapse
|
Parkinson's disease
|
Cocaine addiction
|
Alcoholismhsa04022:cGMP-PKG signaling pathway
|
PANTHER Pathway
|
5HT2 type receptor mediated signaling pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
5HT1 type receptor mediated signaling pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
Dopamine receptor mediated signaling pathway
|
Nicotine pharmacodynamics pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
Nicotine pharmacodynamics pathwayP00002:Alpha adrenergic receptor signaling pathway
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
Reactome
|
Dopamine receptors
|
G alpha (i) signalling eventsR-HSA-390666:Serotonin receptors
|
G alpha (q) signalling eventsR-HSA-390666:Serotonin receptors
|
G alpha (i) signalling eventsR-HSA-390651:Dopamine receptors
|
G alpha (i) signalling eventsR-HSA-390696:Adrenoceptors
|
Adrenaline signalling through Alpha-2 adrenergic receptor
|
Adrenaline,noradrenaline inhibits insulin secretion
|
G alpha (i) signalling events
|
G alpha (z) signalling events
|
Surfactant metabolism
|
WikiPathways
|
Monoamine GPCRs
|
GPCRs, Class A Rhodopsin-like
|
GPCR ligand binding
|
GPCR downstream signaling
|
Nicotine Activity on Dopaminergic Neurons
|
GPCRs, OtherWP732:Serotonin Receptor 2 and ELK-SRF/GATA4 signaling
|
Gastrin-CREB signalling pathway via PKC and MAPK
|
GPCR downstream signalingWP722:Serotonin HTR1 Group and FOS Pathway
|
SIDS Susceptibility Pathways
|
GPCR downstream signalingWP666:Hypothetical Network for Drug Addiction
|
Genes and (Common) Pathways Underlying Drug Addiction
|
GPCRs, OtherWP666:Hypothetical Network for Drug Addiction
|
Nicotine Activity on Dopaminergic NeuronsWP58:Monoamine GPCRs
|
Platelet Aggregation (Plug Formation)
|
Integration of energy metabolism
|
References |
REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 49). |
---|
REF 2 | Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther. 2002 Nov;303(2):791-804. |